Ribo publie des résultats positifs suite à l'essai de Phase 2a réalisé sur le vortosiran - Premières données cliniques au monde sur l'inhibition du facteur XI par pARNi après administration de plusieurs doses chez des patients atteints de coronaropathie

Phase 2positivevortosiranPositive

AI Analysis

Summary

Ribo announced positive Phase 2a trial results for vortosiran, a Factor XI inhibitor, demonstrating first-in-human clinical data for pARNi-based Factor XI inhibition following multiple doses in coronary artery disease patients. The data was presented at the China Pharmaceutical Innovation Conference on July 23, 2026.

Clinical Trial Data

Phase

Primary Endpoint

Met

Outcome Details

Phase 2a trial demonstrated positive results for Factor XI inhibition via pARNi following multiple doses in coronary artery disease patients

Importance:7/10

Sentiment:

0.80

Phase 2 datacardiovascular diseaseRNA interferenceFactor XI inhibitionclinical trial results

Related Companies

$IPIX $CHHE

Read the original article

Published by PR Newswire Pharma on July 23, 2026 11:29 AM

Read Original